Skip to main content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 2/2023

23.02.2023 | original report

Spectrum of renal involvement in MGRS patients: a 6-year study

verfasst von: Dr. Poornima Tadkal, Dr. Vishwanath Siddini, Dr. V. Mahesha, Dr. Sudarshan Ballal, Dr. Rohan Augustine, Dr. Kishore Babu, Dr. Mallikarjun Kalashetty

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 2/2023

Einloggen, um Zugang zu erhalten

Summary

Background and objectives

Monoclonal gammopathy of renal significance (MGRS) includes smoldering B cell or plasma cell clones causing renal disease. Our understanding of MGRS is still evolving and through our study we intend to analyze the spectrum of renal involvement in patients with MGRS in our institution in the last 6 years.

Materials and methods

All patients admitted to our hospital with a diagnosis of MGRS from November 2015 to October 2021 were reviewed. It was a retrospective observational study. History, physical examination, and laboratory investigations were meticulously documented.

Results

During the 6 year study period, 108 patients with monoclonal gammopathy of unknown significance (MGUS) were diagnosed, with 29 (26.85%) of them developing MGRS. Median age of the patients was 55 years with majority being men. On light microscopy, the most common renal biopsy patterns were AL amyloidosis (11 patients), monoclonal immunoglobulin deposition disease (6 patients) followed by proliferative glomerulonephritis with monoclonal IgG deposits in 5 patients.

Conclusions

During the 6 year study period, 108 patients with MGUS were diagnosed, with 29 (26.85%) of them developing MGRS. Serum immunoelectrophoresis was the most sensitive test for paraprotein detection in our study. IgG kappa and IgG lambda were the most common paraprotein patterns on serum immunofixation. On renal biopsy, AL amyloidosis-lambda was the most common, followed by monoclonal immunoglobulin deposition disease and proliferative glomerulonephritis with monoclonal IgG deposition. Serum creatinine and paraprotein measured by the serum-free light chain (SFLC) ratio had a positive correlation (statistically significant). There was no correlation between urine protein creatinine ratio and M protein measured by serum protein electrophoresis (SPEP) or SFLC ratio in MGRS patients. We conclude by saying that in case of suspicion of MGRS, renal biopsy should be considered.
Literatur
3.
Zurück zum Zitat Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand J‑P, et al. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–5. CrossRefPubMed Leung N, Bridoux F, Hutchison CA, Nasr SH, Cockwell P, Fermand J‑P, et al. Monoclonal gammopathy of renal significance: When MGUS is no longer undetermined or insignificant. Blood. 2012;120(22):4292–5. CrossRefPubMed
4.
Zurück zum Zitat Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. Publisher correction: the evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group. Nat Rev Nephrol. 2018;15(2):121. CrossRefPubMedCentral Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D’Agati VD, et al. Publisher correction: the evaluation of monoclonal gammopathy of renal significance: a consensus report of the international kidney and monoclonal gammopathy research group. Nat Rev Nephrol. 2018;15(2):121. CrossRefPubMedCentral
5.
Zurück zum Zitat Jain A, Haynes R, Kothari J, Khera A, Soares M, Ramasamy K. Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Adv. 2019;3(15):2409–23. CrossRefPubMedPubMedCentral Jain A, Haynes R, Kothari J, Khera A, Soares M, Ramasamy K. Pathophysiology and management of monoclonal gammopathy of renal significance. Blood Adv. 2019;3(15):2409–23. CrossRefPubMedPubMedCentral
6.
Zurück zum Zitat Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931–41. CrossRefPubMed Leung N, Bridoux F, Nasr SH. Monoclonal gammopathy of renal significance. N Engl J Med. 2021;384(20):1931–41. CrossRefPubMed
7.
Zurück zum Zitat Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, et al. Long term outcomes in monoclonal gammopathy of renal significance. Br J Haematol. 2019;186(5):706–16. CrossRefPubMed Khera A, Panitsas F, Djebbari F, Kimberger K, Stern S, Quinn J, et al. Long term outcomes in monoclonal gammopathy of renal significance. Br J Haematol. 2019;186(5):706–16. CrossRefPubMed
8.
Zurück zum Zitat Klomjit N, Leung N, Fervenza F, Sethi S, Zand L. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31(10):2400–11. CrossRefPubMedPubMedCentral Klomjit N, Leung N, Fervenza F, Sethi S, Zand L. Rate and predictors of finding monoclonal gammopathy of renal significance (MGRS) lesions on kidney biopsy in patients with monoclonal gammopathy. J Am Soc Nephrol. 2020;31(10):2400–11. CrossRefPubMedPubMedCentral
Metadaten
Titel
Spectrum of renal involvement in MGRS patients: a 6-year study
verfasst von
Dr. Poornima Tadkal
Dr. Vishwanath Siddini
Dr. V. Mahesha
Dr. Sudarshan Ballal
Dr. Rohan Augustine
Dr. Kishore Babu
Dr. Mallikarjun Kalashetty
Publikationsdatum
23.02.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 2/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-023-00873-6

Weitere Artikel der Ausgabe 2/2023

memo - Magazine of European Medical Oncology 2/2023 Zur Ausgabe

editorial

ESMO 2022